What is OM1?
OM1 specializes in delivering AI-powered, real-world data and insights designed to enhance personalized medicine and observational research. The company provides a robust suite of tech-enabled solutions for both prospective and retrospective evidence generation, catering to global healthcare organizations that require advanced analytics and custom data cohorts. By integrating extensive data networks with sophisticated machine learning models, OM1 enables stakeholders to improve patient outcomes and operational efficiency. Recognized for its innovation in RWE analytics, the firm serves as a critical infrastructure provider for the modern healthcare ecosystem, bridging the gap between raw clinical data and actionable medical intelligence.
How much funding has OM1 raised?
OM1 has raised a total of $171M across 4 funding rounds:
Series A
$15M
Series B
$21M
Private Equity
$50M
Other Financing Round
$85M
Series A (2017): $15M with participation from Wanxiang Healthcare Investments, General Catalyst, and 7wireVentures
Series B (2018): $21M led by General Catalyst, 7wireVentures, and Polaris Partners
Private Equity (2019): $50M supported by BA Venture Partners, General Catalyst (GC), 7wireVentures, and Polaris Partners
Other Financing Round (2021): $85M featuring Breyer Capital, D1 Capital Partners, and Kaiser Permanente
Key Investors in OM1
General Catalyst
General Catalyst is a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors, leveraging deep operational experience to accelerate growth.
7wireVentures
7wire Ventures builds and invests in early-stage digital health companies, focusing on creating informed and connected health consumers through innovative AI and personalized coaching solutions.
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, providing deep coaching and resources for long-term growth.
What's next for OM1?
Looking ahead, the infusion of capital from the most recent financing round is expected to accelerate OM1's expansion into new therapeutic verticals and enhance its proprietary data analytics platform. As the healthcare industry increasingly shifts toward value-based care, OM1 is well-positioned to capitalize on the growing demand for high-fidelity, real-world evidence. The company's strategic roadmap likely includes deepening its integration with large-scale health systems and expanding its footprint in global markets. By maintaining its focus on technological excellence and strategic partnerships, OM1 is poised to sustain its growth trajectory and solidify its role as an essential partner for life sciences companies and healthcare providers seeking to navigate the complexities of modern medicine.
See full OM1 company page
